1328 Endometrial cancer in young women: treatment outcomes

Introduction/Background Endometrial cancer is the third gynecological cancer in Tunisia. It mainly occurs in postmenopausal women (75%). However, it can hit young women aged under 40 years in 5% of cases. Objectif: Describe clinical characteristics and therapeutic results of endometrial cancer in young women in a Tunisian population. Methodology Retrospective study of 6 patients, aged less than 40 years, with endometrial cancer treated in the department of oncological-radiotherapy of the Farhat-Hached Hospital, Sousse, Tunisia between 1995 and 2020. Results The median age was 31,5years 16–39. At the time of diagnosis, 5 patients were childless (83.3%) and 2 had primary infertility. Only one patient had diabetes and 2 patients were overweight. The median patient delay was 5 months 2–24. The main circumstances of discovery were metrorrhagia and pelvic pain in 50% and 33,3% of cases, respectively. All patients underwent total hysterectomy with bilateral adnexectomy. Pelvic lymph node dissection was performed in 5 cases (83,3%). The histopathological analysis showed endometrioid adenocarcinoma in 2 patients, sarcoma in 2 patients and Mullerian tumor in 2 cases. Surgical margins were clear in all cases. According to the 2018-FIGO classification, 3 tumors were classified as stage IA, 2 as stage II and 1 as stage IIIb. All patients received pelvic radiotherapy, with a dose of 50Gy in 5 cases and 54Gy in one case, using two-dimensional radiotherapy in 4 cases and three-dimensional conformal radiotherapy in 2 cases. chemotherapy was done in 2 cases. After a median follow-up of 21months 12–252, 4 patients (66,7%) were in complete remission and 2 patients died due to metastatic relapse. Conclusion Endometrial cancer in young women is a rare entity with a rather good prognosis. However, the place of conservative treatment for the early stages in these women of childbearing age, most of whom want to preserve their fertility, remains to be defined. Disclosures The authors declare that they do not have a conflict of interest.